title: Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.
abstract: This study examined whether control of hyperglycemia with a new SGLT2 inhibitor, luseogliflozin, given alone or in combination with lisinopril could prevent the development of renal injury in diabetic Dahl salt-sensitive (Dahl S) rats treated with streptozotocin (Dahl-STZ). Blood glucose levels increased from normoglycemic to hyperglycemic levels after treatment of STZ in Dahl S rats. Chronic treatment of Dahl-STZ rats with luseogliflozin (10 mg/kg/day) increased the fractional excretion of glucose and normalized blood glucose and HbA1c levels. Lisinopril (20 mg/kg/day) reduced blood pressure from 145 ± 9 to 120 ± 5 mmHg in Dahl-STZ rats, while luseogliflozin had no effect on blood pressure. Combination therapy reduced blood pressure more than that seen in the rats treated with luseogliflozin or lisinopril alone. Dahl-STZ rats exhibited hyperfiltration, mesangial matrix expansion, severe progressive proteinuria, focal glomerulosclerosis and interstitial fibrosis. Control of hyperglycemia with luseogliflozin reduced the degree of hyperfiltration and renal injury but had no effect on blood pressure or the development of proteinuria. Treatment with lisinopril reduced hyperfiltration, proteinuria and renal injury in Dahl-STZ rats. Combination therapy afforded greater renoprotection than administration of either drug alone. These results suggest that long-term control of hyperglycemia with luseogliflozin, especially in combination with lisinopril to lower blood pressure, attenuates the development of renal injury in this rat model of advanced diabetic nephropathy.
authors.affiliation: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi Saitama, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Kojima
authors.affiliation: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi.
authors.forename: Jan M
authors.initials: JM
authors.lastname: Williams
authors.affiliation: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi.
authors.forename: Tiffani N
authors.initials: TN
authors.lastname: Slaughter
authors.affiliation: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi Saitama, Japan.
authors.forename: Sota
authors.initials: S
authors.lastname: Kato
authors.affiliation: Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi Saitama, Japan te-takahashi@so.taisho.co.jp.
authors.forename: Teisuke
authors.initials: T
authors.lastname: Takahashi
authors.affiliation: Pharmaceutical Business Planning, Taisho Pharmaceutical Co., Ltd., Toshima-ku Tokyo, Japan.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Miyata
authors.affiliation: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Roman
keywords: ACE inhibitor; SGLT2 inhibitor; diabetic nephropathy; hypertension; insulin